ATE225666T1 - Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung - Google Patents

Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung

Info

Publication number
ATE225666T1
ATE225666T1 AT95901918T AT95901918T ATE225666T1 AT E225666 T1 ATE225666 T1 AT E225666T1 AT 95901918 T AT95901918 T AT 95901918T AT 95901918 T AT95901918 T AT 95901918T AT E225666 T1 ATE225666 T1 AT E225666T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
acute
producing
kidney disease
Prior art date
Application number
AT95901918T
Other languages
English (en)
Inventor
Howard R Higley
Christopher A Maack
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE225666T1 publication Critical patent/ATE225666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95901918T 1993-11-15 1994-11-15 Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung ATE225666T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15286293A 1993-11-15 1993-11-15
PCT/US1994/013178 WO1995013824A1 (en) 1993-11-15 1994-11-15 Method of treating renal disease by administering igf-i and igfbp-3

Publications (1)

Publication Number Publication Date
ATE225666T1 true ATE225666T1 (de) 2002-10-15

Family

ID=22544774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901918T ATE225666T1 (de) 1993-11-15 1994-11-15 Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung

Country Status (8)

Country Link
US (1) US5723441A (de)
EP (1) EP0732933B1 (de)
JP (1) JPH09509141A (de)
AT (1) ATE225666T1 (de)
AU (1) AU690941B2 (de)
CA (1) CA2176709A1 (de)
DE (1) DE69431527T2 (de)
WO (1) WO1995013824A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
EP0980252B1 (de) 1997-05-05 2004-10-06 Curis, Inc. Therapien zur behandlung von akutem nierenversagen
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AU2001276608A1 (en) * 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
JP2004537036A (ja) * 2001-03-28 2004-12-09 ヘスカ コーポレイション 動物において早期腎疾患を検出する方法
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
CA2470026A1 (en) * 2001-12-14 2003-06-26 Centocor, Inc. Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
US20040152170A1 (en) * 2001-12-14 2004-08-05 Lee Chichang Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
US20030166147A1 (en) * 2001-12-14 2003-09-04 Lee Chichang Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
EP1578360A4 (de) * 2002-08-28 2009-10-21 Curis Inc Gleichzeitige verabreichung von morphogenen und ace-hemmern bei der behandlung von chronischer niereninsuffizienz
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
WO2006034832A2 (en) * 2004-09-27 2006-04-06 Univ Muenchen L Maximilians Use of igfbp-2 in senescence diseases and for the maintenance of organ functions
CN101107012A (zh) * 2004-11-24 2008-01-16 希尔氏宠物营养品公司 改进动物异生素物质肝清除率的方法
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
WO2006074089A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US9272033B2 (en) * 2005-04-19 2016-03-01 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
JP2008539274A (ja) * 2005-04-29 2008-11-13 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコの寿命を延長する方法
BRPI0610060A2 (pt) * 2005-05-20 2010-05-25 Hills Pet Nutrition Inc método para promover a saúde ou bem estar em um animal adulto, método para regular a ingestão de rações por um animal adulto, kit, meios para comunicar informação sobre ou instruções para promover a saúde ou bem estar em um animal adulto, método para aumentar a retenção de nitrogênio por um animal adulto, processo para fabricar uma ração, produto, e, ração
RU2412608C2 (ru) * 2005-06-29 2011-02-27 Хилл`С Пет Ньютришн, Инк. Кормовая композиция для профилактики заболевания почек, способ ее получения, способ профилактики заболевания почек, набор
US8492432B2 (en) * 2005-08-17 2013-07-23 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
EP1952823A1 (de) * 2007-01-30 2008-08-06 AM-Pharma B.V. Verwendung von alkalischer Phosphatase bei der Behandlung eingeschränkter Nierenfunktion
KR102166110B1 (ko) 2014-01-24 2020-10-16 에이엠-파마 비.브이. 키메라 알칼리성 포스파타제-유사 단백질
CN106459143A (zh) 2014-01-24 2017-02-22 安-法玛公司 碱性磷酸酶的下游处理

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure

Also Published As

Publication number Publication date
WO1995013824A1 (en) 1995-05-26
EP0732933A4 (de) 1996-11-06
CA2176709A1 (en) 1995-05-26
DE69431527T2 (de) 2003-06-26
AU690941B2 (en) 1998-05-07
AU1098295A (en) 1995-06-06
US5723441A (en) 1998-03-03
DE69431527D1 (de) 2002-11-14
EP0732933A1 (de) 1996-09-25
JPH09509141A (ja) 1997-09-16
EP0732933B1 (de) 2002-10-09

Similar Documents

Publication Publication Date Title
DE69431527D1 (de) Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
Rossi et al. Morphological study of the laryngeal muscles in man: Insertions and courses of the muscle fibres, motor end-plates and proprioceptors
Tonna et al. Autoradiographic studies of cell proliferation in the periosteum of intact and fractured femora of mice utilizing DNA labeling with H3-thymidine.
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DE68905203D1 (de) Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DE69332624D1 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE69228949D1 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
ATE271880T1 (de) Methoden zur behandlung von diabetes
EA200000058A1 (ru) Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
AU1870097A (en) Use of a medicament and use of mixture of substances to produce a medicament
DE69719525T2 (de) Verwendung von proteine als mittel gegen autoimmunekrankheiten
Delano et al. Home and medical center hemodialysis: Dollar comparison and payback period
YU17999A (sh) Novi derivati pentaeritrita, njihova izrada i primena kao i međuproizvodi za njihovu sintezu
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
Höllt et al. Endorphins in schizophrenia: hemodialysis/hemoperfusion are ineffective in clearing β-Leu5-endorphin and β-endorphin from human plasma
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
Sehouli et al. Benign symmetric lipomatosis—a therapeutic dilemma?
ES2111068T3 (es) Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.
SU1664325A1 (ru) Способ лечени гнездного облысени
Dober Epileptische Psychosen ohne epileptische Anfälle und ihre Differentialdiagnostik
Ripka Case for Certification
Chapman et al. Overtime Payments
Murley Unity of Interest
Muir Effects of Tablet Colour

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties